Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

hypertrophic cardiomyopathy - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

hypertrophic cardiomyopathy

MONDO:0005045

Also known as:hypertrophic obstructive cardiomyopathyhypertrophic subaortic stenosisobstructive hypertrophic cardiomyopathy

Find Clinical TrialsTrials

Overview

A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract.

Treatments2 FDA approved

Clinical Trials120 registered · 53 recruiting

Patient Orgs1 organizations · Hypertrophic Cardiomyopathy Association

Diagnosis

Biomarker and diagnostic research for hypertrophic cardiomyopathy has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for hypertrophic cardiomyopathy, including ALCOHOL (DEHYDRATED ALCOHOL, approved 2018) and MAVACAMTEN (CAMZYOS, approved 2022).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

120 clinical trials registered, 53 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 7 PHASE4, 7 PHASE3, 9 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07372196](https://clinicaltrials.gov/study/NCT07372196)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:02 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

Hypertrophic Cardiomyopathy AssociationPrimary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:217569

Questions for Your Care Team

→What are the benefits and potential side effects of DEHYDRATED ALCOHOL for managing hypertrophic cardiomyopathy?
→Are any of the 120 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with Hypertrophic Cardiomyopathy Association and other patient organizations for support?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	142	31%
Other research	71	16%
Clinical study results	69	15%
Disease patterns and progression	47	10%
Patient case studies	40	9%
Laboratory research	40	9%
Testing and diagnosis research	27	6%
New treatment approaches	19	4%

Kisho

hypertrophic cardiomyopathy

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Natural Missplicing Events Amplified by an Elusive Deep-Intronic MYBPC3 Variant Cause Hypertrophic Cardiomyopathy.

Left Atrium Myocardial Remodeling and Prognostic Marker Derived from CMR Feature Tracking in Pediatric Hypertrophic Cardiomyopathy.

[Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].

Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno

hypertrophic cardiomyopathy

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Natural Missplicing Events Amplified by an Elusive Deep-Intronic MYBPC3 Variant Cause Hypertrophic Cardiomyopathy.

Left Atrium Myocardial Remodeling and Prognostic Marker Derived from CMR Feature Tracking in Pediatric Hypertrophic Cardiomyopathy.

[Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].

Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno